MedTrace Logo

Motor Unit Abnormalities After Experimentally Induced Sensitization

NCT04361149 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-04-24

No results posted yet for this study

Summary

Central sensitization is a condition that represents a cascade of neurological adaptations, resulting in an amplification of nociceptive responses from noxious and non-noxious stimuli. This phenomenon presents itself in a vast majority of chronic pain syndromes. Previous evidence has shown that central sensitization results in afferent nociceptor and dorsal horn abnormalities; however, a link between whether this abnormality translates into motor output and more specifically, ventral horn abnormalities, needs to be further explored. Twenty participants were recruited and either a topical capsaicin or a placebo topical cream was applied to their back to induce a transient state of sensitization. Surface electromyography(sEMG) and intramuscular electromyography(iEMG) were used to record motor unit activity from the trapezius and infraspinatus muscles before and after application of capsaicin/placebo. Motor unit recruitment and variability were analyzed in the sEMG and iEMG respectively

Conditions

  • Central Sensitisation
  • Motor Disorders

Interventions

DRUG

Capsaicin Topical Cream (0.075%)

Capsaicin cream will be administered as a topical skin cream

DEVICE

Delsys Trigno Galileo System

A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.

DEVICE

Excaliber, Natus Medical

Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.

OTHER

Placebo Cream

Placebo cream will be administered as a topical skin cream

Sponsors & Collaborators

  • Toronto Rehabilitation Institute

    lead OTHER

Principal Investigators

  • Dinesh Kumbahre, PhD · Toronto Rehabilitation Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2019-12-20
Completion
2020-03-10
FDA Drug
Yes
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361149 on ClinicalTrials.gov